{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-068816","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2023-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.723026+00:00","generated_at":"2026-06-07T16:03:35.448358+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"KalVista hits Phase 3 attack target for sebetralstat; NDA on track for H1 2024","bullets":["Phase 3 KONFIDENT trial achieved targeted number of attacks; data readout early 2024, NDA filing expected H1 2024.","Received Orphan Drug Status from Switzerland for sebetralstat, providing 15-year market protection.","Net loss of $27.7M ($0.80/share) for Q2 FY24 vs. $22.3M ($0.90/share) year ago; revenue nil.","Cash, equivalents and marketable securities $103.2M at Oct 31, 2023, down from $149.4M at Apr 30, 2023.","R&D expenses $19.1M; G&A expenses $10.7M, both up YoY due to trial costs and commercial build-out."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-068816","json":"https://secwatch.observer/filing/0000950170-23-068816.json","markdown":"https://secwatch.observer/filing/0000950170-23-068816.md","text":"https://secwatch.observer/filing/0000950170-23-068816.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/0000950170-23-068816-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/kalv-20231207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:03:35.448358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2b844ff92a76e7f5c404471fecc84ad0372e68a","claim":"KalVista Pharmaceuticals, Inc. reported the three months ended October 31, 2023 results: revenue No revenue was recognized, net income Net loss was $27.7 million, EPS $(0.80) per weighted average basic and diluted share.","evidence_excerpt":"On December 7, 2023, KalVista Pharmaceuticals, Inc. (the “Company”) reported its financial results for the fiscal quarter ended October 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017023068816/0000950170-23-068816-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended October 31, 2023"},{"label":"Revenue","value":"No revenue was recognized"},{"label":"Net income","value":"Net loss was $27.7 million"},{"label":"EPS","value":"$(0.80) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}